Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials
Dario Giugliano, Miriam Longo, Maria Ida Maiorino, et al.
Diabetes Research and Clinical Practice (2020) Vol. 162, pp. 108114-108114
Closed Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
Dario Giugliano, Miriam Longo, Simona Signoriello, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 99
Treatment of chronic kidney disease in older populations
Seiji Kishi, Hiroyuki Kadoya, Naoki Kashihara
Nature Reviews Nephrology (2024) Vol. 20, Iss. 9, pp. 586-602
Closed Access | Times Cited: 17
GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
Thomas Karagiannis, Απόστολος Τσάπας, Eleni Athanasiadou, et al.
Diabetes Research and Clinical Practice (2021) Vol. 174, pp. 108737-108737
Closed Access | Times Cited: 98
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 57
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Ema Schönberger, Vjera Mihaljević, Kristina Steiner, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 17, pp. 6671-6671
Open Access | Times Cited: 28
2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care
Samuel Seidu, Xavier Cos, Stephen Brunton, et al.
Primary care diabetes (2022) Vol. 16, Iss. 2, pp. 223-244
Open Access | Times Cited: 31
The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
Marc Evans, Angharad R. Morgan, Sarah Davies, et al.
Age and Ageing (2022) Vol. 51, Iss. 10
Open Access | Times Cited: 29
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 34
Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotype
Alan J. Sinclair, Daniel Pennells, Ahmed H. Abdelhafiz
Aging Clinical and Experimental Research (2022) Vol. 34, Iss. 9, pp. 1949-1967
Open Access | Times Cited: 28
Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0·9 million adults with Diabetes in Hong Kong (2002–2019)
Aimin Yang, Hongjiang Wu, Eric S. H. Lau, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 26, pp. 100509-100509
Open Access | Times Cited: 25
Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis
Anika Bilal, Fanchao Yi, Gonzalo Romero Gonzalez, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 8, pp. 108783-108783
Open Access | Times Cited: 4
Kidney outcomes with SGLT2 inhibitor vs. DPP4 inhibitor use in older adults with diabetes
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Nephrology Dialysis Transplantation (2024)
Closed Access | Times Cited: 4
Oral Hypoglycaemic Therapy
Nahian Kazi, Ahmed H. Abdelhafiz
(2025), pp. 31-40
Closed Access
Managing Diabetes in Older Adults: Current Approaches in Long-Term Care Facilities
Thaer Idrees, Guillermo E. Umpierrez, Sriya Kantipudi, et al.
Current Diabetes Reports (2025) Vol. 25, Iss. 1
Closed Access
Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy
Ahmed H. Abdelhafiz, Alan J. Sinclair
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 9, pp. 107639-107639
Closed Access | Times Cited: 30
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
Update on the management of diabetes in long-term care facilities
Thaer Idrees, Iris A. Castro-Revoredo, Alexandra L. Migdal, et al.
BMJ Open Diabetes Research & Care (2022) Vol. 10, Iss. 4, pp. e002705-e002705
Open Access | Times Cited: 18
Careful use to minimize adverse events of oral antidiabetic medications in the elderly
André Scheen
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 16, pp. 2149-2165
Closed Access | Times Cited: 23
SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
Birgit Janssens, S. Caerels, Chantal Mathieu
Therapeutic Advances in Endocrinology and Metabolism (2020) Vol. 11
Open Access | Times Cited: 19
Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000–2019
Kyung Ae Lee, Heung Yong Jin, Yu Ji Kim, et al.
Journal of Korean Medical Science (2021) Vol. 36, Iss. 36
Open Access | Times Cited: 17
Risk Factors and Cardiovascular Disease in the Elderly
Pablo Díez‐Villanueva, César Jiménez-Méndez, Clara Bonanad, et al.
Reviews in Cardiovascular Medicine (2022) Vol. 23, Iss. 6, pp. 188-188
Open Access | Times Cited: 12
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Dae Jung Kim
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 5, pp. 837-846
Closed Access | Times Cited: 2
Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society
Michikazu Nakai, Yoshitaka Iwanaga, Koshiro Kanaoka, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 10, pp. 100135-100135
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top